# Temozolomide and Radiation Therapy With or Without Bevacizumab in Treating Patients With Newly Diagnosed Glioblastoma

> **NCT00884741** · PHASE3 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 637 (actual)

## Conditions studied

- Glioblastoma
- Gliosarcoma
- Supratentorial Glioblastoma

## Interventions

- **RADIATION:** 3-Dimensional Conformal Radiation Therapy
- **BIOLOGICAL:** Bevacizumab
- **RADIATION:** Intensity-Modulated Radiation Therapy
- **OTHER:** Laboratory Biomarker Analysis
- **OTHER:** Placebo
- **OTHER:** Quality-of-Life Assessment
- **DRUG:** Temozolomide

## Key facts

- **NCT ID:** NCT00884741
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-04-15
- **Primary completion:** 2013-03-17
- **Final completion:** 2013-03-17
- **Target enrollment:** 637 (ACTUAL)
- **Last updated:** 2019-07-24

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00884741

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00884741, "Temozolomide and Radiation Therapy With or Without Bevacizumab in Treating Patients With Newly Diagnosed Glioblastoma". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00884741. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*